Study guide

12.1 Non-Sterile Compounding & USP <795> Standards

Utah MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Utah Pharmacy Regulatory Framework, Facility Licensing & the PIC

1.1 DOPL, the Utah State Board of Pharmacy & the Sources of Utah Pharmacy Law 1.2 Federal vs. Utah Law: Following the Stricter Standard 1.3 Utah Pharmacy License Classes (A–E) & Facility Licensing 1.4 The Pharmacist-in-Charge (PIC): Duties, Self-Audits & Notifications 1.5 Facility Inspections, Ownership & Location Changes, Closing & Facility Discipline

2 Chapter 2: Pharmacist, Intern & Technician Licensure and Personnel

2.1 Pharmacist Licensure, the NAPLEX & Utah MPJE, and Licensure by Endorsement 2.2 License Renewal, Continuing Education & Reinstatement 2.3 Pharmacy Interns & Preceptors 2.4 Pharmacy Technicians, Technician Trainees & Supportive Personnel

3 Chapter 3: Unlawful & Unprofessional Conduct, Discipline, and Impairment

3.1 Unlawful Conduct, Criminal Penalties, Fines & the Disciplinary Process 3.2 Unprofessional Conduct, the APhA Code of Ethics & Utah's Conscience Law 3.3 Impairment, the Utah Professionals Health Program & Reinstatement

4 Chapter 4: Prescription Issuance, Prescriber Authority & Electronic Prescribing

4.1 Prescriber Scope of Authority in Utah 4.2 Required Prescription Elements, Oral & Faxed Orders, and Alterations 4.3 Mandatory Electronic Prescribing of Controlled Substances (EPCS) in Utah 4.4 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

5 Chapter 5: Patient Counseling, Prospective DUR, Confidentiality & Records

5.1 Patient Counseling: The Offer, Who May Counsel & Delivered Prescriptions 5.2 Prospective Drug Utilization Review & Patient Medication Profiles 5.3 Confidentiality, HIPAA & Protected Health Information 5.4 Pharmacy Records, Retention Periods & Facility Operating Standards

6 Chapter 6: Expanded Practice: Collaboration, Pharmacist Prescribing & Drug Administration

6.1 Collaborative Pharmacy Practice, Drug Therapy Management & Administration of Drugs 6.2 Self-Administered Hormonal Contraception: Standing Order & Pharmacist Prescribing 6.3 Pharmacist Prescribing Under Utah Code § 58-17b-627: Tobacco Cessation, HIV PrEP/PEP, Fluoride & Epinephrine 6.4 Vaccine Administration: DOPL's Protocol, Delegation, Emergencies & USIIS Reporting

7 Chapter 7: Opioid Overdose Prevention, Emergency Refills & Returned or Donated Drugs

7.1 Naloxone & Opioid-Safety Laws in Utah 7.2 Emergency Refills, Combined Refills & Insulin Continuity 7.3 Returned Drugs, Consumer Disposal & the Charitable Prescription Drug Recycling Program

8 Chapter 8: Controlled Substance Schedules, Registration & Security in Utah

8.1 Controlled Substance Schedules: Federal CSA & Utah-Specific Scheduling 8.2 DEA Registration & Facility Licensing 8.3 Controlled Substance Storage & Physical Security

9 Chapter 9: Dispensing Controlled Substances & the Utah Controlled Substance Database

9.1 Schedule II Prescriptions: 30-Day Window, One-Month Supply, Multiple Prescriptions & the 7-Day Acute Limit 9.2 Schedule II Partial Fills, Emergency Oral Orders & Methadone Emergency Orders 9.3 Schedule III–V Prescriptions: Refill Limits, the 80% Rule & Controlled Substance Transfers 9.4 The Utah Controlled Substance Database (CSD)

10 Chapter 10: Dispensing Standards: Labeling, Substitution, Refills, Packaging, Product Integrity & OTC Products

10.1 Prescription Labels: Utah Minimum Elements, Controlled Substance & Opioid Warnings, and Special Labels 10.2 Drug Product Selection: Generic Equivalents, Therapeutically Similar Drugs & Interchangeable Biologics 10.3 Legend-Drug Prescription Validity, Refills & Transfers 10.4 Poison Prevention Packaging Act (PPPA) & Special Packaging 10.5 Drug Product Conditions That Prohibit Dispensing: Adulterated, Misbranded, Outdated, Recalled & Suspect Products 10.6 Nonprescription Products: OTC Labeling & Packaging, Pseudoephedrine, Iodine, Schedule V & Other Restricted OTC Sales

11 Chapter 11: Acquisition, Inventory, Loss, Distribution & Delivery

11.1 Ordering Schedule II Substances: DEA Form 222 & CSOS 11.2 Controlled Substance Inventories & Utah's Schedule II Perpetual Inventory 11.3 Theft, Significant Loss & Disposal of Controlled Substances 11.4 Drug Acquisition & Distribution, Office-Use Sales, and Delivering Prescriptions to Patients

12 Chapter 12: Compounding Standards, USP Chapters & Hazardous Drugs

12.1 Non-Sterile Compounding & USP <795> Standards 12.2 Sterile Compounding & USP <797> Standards 12.3 Hazardous Drug Handling & USP <800> Standards

13 Chapter 13: Institutional, Central Processing, Remote Dispensing, Specialty Outlets & Automation

13.1 Institutional Practice: Hospitals, Pharmaceutical Administration Facilities & Emergency Drug Kits 13.2 Centralized Prescription Processing, Telepharmacy & Remote Dispensing Pharmacies 13.3 Nuclear Pharmacies, Class E Outlets & Dispensing Medical Practitioners 13.4 Automated Pharmacy Systems, Quality Assurance & Pharmacy Audits

12.1 Non-Sterile Compounding & USP <795> Standards

Key Takeaways Explain This Topic AI

Traditional 503A pharmacy compounding requires a patient-specific prescription (or limited anticipatory compounding) and is exempt from FDA cGMP, premarket approval, and adequate directions for use, while 503B outsourcing facilities compound bulk orders for office use under full cGMP.

Utah Admin. Code R156-17b-614e requires every compounding licensee to follow USP <795>, <797>, and <825>. Failing to comply with USP <795> or <797> is unprofessional conduct under R156-17b-502(2).

A Master Formulation Record (MFR) is the permanent master recipe and blueprint created prior to compounding, whereas the Compounding Record (CR) is the execution log documenting the specific batch, component lot numbers, actual quantities, and verification.

Revised USP <795> default beyond-use date (BUD) limits without stability data are: non-preserved aqueous dosage forms: 14 days refrigerated (2°C-8°C); preserved aqueous forms: 35 days at room temperature or refrigerated; non-aqueous forms: 90 days; and solid dosage forms: 180 days.

A compounded preparation's beyond-use date can never exceed the shortest manufacturer expiration date of any starting active pharmaceutical ingredient (API) or raw component used in the formulation.

Last updated: September 2026

12.1 Non-Sterile Compounding & USP <795> Standards

Compounding is a foundational aspect of pharmacy practice that provides customized medications tailored to the unique clinical needs of individual patients when commercially manufactured products are unavailable, unsuitable, or clinically contraindicated. Following the catastrophic 2012 fungal meningitis outbreak linked to the New England Compounding Center (NECC), Congress enacted the Drug Quality and Security Act (DQSA) of 2013, fundamentally overhauling federal compounding jurisprudence. In Utah, compounding practice is regulated under the Utah Pharmacy Practice Act (Utah Code Ann. § 58-17b-101 et seq.) and DOPL's compounding rule, Utah Admin. Code R156-17b-614e. That rule requires compliance with USP <795>, <797>, and <825> and sets Utah's own schedule and modifications for USP <800>. Candidates preparing for the Utah MPJE must master the statutory divide between traditional pharmacy compounding and outsourcing facilities, facility sanitation and water standards, formulation documentation, and strict beyond-use dating (BUD) limits.

Regulatory Framework: DQSA Section 503A vs. Section 503B

The DQSA amended the federal Food, Drug, and Cosmetic Act (FDCA) by establishing a two-tiered statutory architecture that separates traditional pharmacy compounding from commercial-scale sterile and non-sterile compounding operations:

Section 503A Traditional Pharmacy Compounding (21 U.S.C. § 353a)

Section 503A applies to licensed state pharmacies and federal facilities that compound medications pursuant to an individual, patient-specific prescription order:

Patient-Specific Mandate : A 503A pharmacy must compound upon receipt of a valid prescription order for an identified patient, or in limited quantities before receipt of a valid prescription order (anticipatory compounding) based on a previously observed, regular history of receiving valid prescription orders from a specific prescriber.

Statutory Exemptions : If a compound complies with Section 503A, it is exempt from three massive FDCA provisions: (1) Current Good Manufacturing Practice (cGMP under 21 U.S.C. § 351(a)(2)(B) and 21 CFR Parts 210/211); (2) FDA premarket approval / New Drug Application (NDA/ANDA) requirements under 21 U.S.C. § 355; and (3) Adequate directions for use labeling mandates under 21 U.S.C. § 352(f)(1).

Primary Oversight : Regulated primarily by state boards of pharmacy (DOPL in Utah) and must comply with applicable USP compounding chapters (<795>, <797>, <800>).

Key Restrictions : A 503A pharmacy may not compound preparations that are "essentially copies" of commercially available drug products without a significant change producing an identifiable clinical difference for an individual patient (e.g., removing a preservative causing an allergy, or formulating an oral liquid for a pediatric dysphagic patient). Furthermore, 503A pharmacies are prohibited from distributing more than 5% of their total prescription orders interstate unless their state has entered into a Standard Memorandum of Understanding (MOU) with the FDA.

Section 503B Outsourcing Facilities (21 U.S.C. § 353b)

Section 503B established a voluntary federal registration category for facilities that compound sterile and non-sterile drugs in bulk:

Office-Use Distribution : 503B facilities may compound and distribute large batches to hospitals, surgery centers, and physician clinics for "office use" without receiving patient-specific prescriptions.

Regulatory Oversight : Directly regulated and inspected by the FDA on a risk-based schedule.

Mandatory cGMP Compliance : Unlike 503A pharmacies, 503B outsourcing facilities are strictly subject to full FDA cGMP regulations , including rigorous environmental monitoring, process validation, continuous stability testing, and batch-release sterility testing.

Exemptions & Prohibitions : Exempt from NDA/ANDA premarket approval and adequate directions for use, but subject to mandatory adverse event reporting within 15 calendar days, biannual electronic reporting of all compounded drug products to the FDA, and specific container labeling ("This is a compounded drug"). Compounding must occur under the direct personal supervision of a licensed pharmacist.

Regulatory Dimension Section 503A Traditional Pharmacy Section 503B Outsourcing Facility

Prescription Requirement Patient-specific prescription mandatory (or limited anticipation) No patient-specific prescription required (bulk "office use")

Governing Authority State Board of Pharmacy / DOPL Food and Drug Administration (FDA)

Compliance Baseline USP General Chapters (<795>, <797>, <800>) Full FDA cGMP (21 CFR Parts 210/211) & USP Chapters

  • Exemption from cGMP Exempt from cGMP requirements Subject to strict cGMP mandates
  • Exemption from NDA/ANDA Exempt from FDA new drug approval Exempt from FDA new drug approval

Reporting Mandates Standard state dispensing records (5-year retention in Utah) Biannual drug listing reports to FDA; 15-day adverse event reporting

Interstate Limits Capped at 5% of total prescriptions (unless state signs FDA MOU) No percentage limit on interstate distribution

Important

Utah law (Utah Code § 58-17b-624) lets a pharmacy repackage or compound a non-controlled drug for sale to a practitioner labeled "for office use only," for administration in the office and not for dispensing. DOPL's rule (R156-17b-624) requires full compliance with federal law, including the FDCA. Under federal law, section 503A exempts compounding based on patient-specific prescriptions (or limited anticipatory compounding). Compounding stock for clinic "office use" without patient-specific prescriptions generally requires an FDA-registered section 503B outsourcing facility . A Class A pharmacy should not treat the Utah office-use statute as permission to act outside section 503A.

Utah Statutory Framework & Incorporation of USP <795>

Under Utah Code § 58-17b-102(18) , compounding is preparing, mixing, assembling, packaging, or labeling a limited quantity of a drug, sterile product, or device:

as the result of a practitioner's prescription or initiative based on the practitioner, patient, and pharmacist relationship;

for research, teaching, or chemical analysis (not for sale or dispensing); or

in anticipation of prescriptions based on routine, regularly observed prescribing patterns .

Compounding does not include preparing drugs for sale to another pharmacist or pharmaceutical facility , preparing a dosage form regularly and commonly available from a manufacturer , or preparing a drug withdrawn from the market for safety reasons . DOPL's rule also excludes reconstitution or mixing done according to the manufacturer's approved labeling , and adding therapeutically inert flavoring that does not exceed 5% of the total volume of a commercially available liquid (R156-17b-102(13)).

Under Utah Admin. Code R156-17b-614e , a licensee engaged in sterile or nonsterile compounding must follow USP <797> (except that a smoke study is required only for new construction or when equipment is physically moved within the cleanroom), USP <795> , and USP <825> (radiopharmaceuticals). These standards apply to every Utah pharmacy or licensee that compounds, wherever the patient is located. Consequences:

Failing to comply with USP <795> or <797> is unprofessional conduct (R156-17b-502(2)).

Compounding a dosage form commonly available from a manufacturer in the prescribed strength and quantity is unprofessional conduct (§ 58-17b-502(1)(m)).

A compounded drug that is adulterated or misbranded may not be dispensed (§ 58-17b-502(1)(c)).

Compounded prescription labels need the generic name and the quantity or concentration of each active ingredient . Sterile parenterals also need the diluent , lot number , and "compounded preparation" (R156-17b-614a(2)).

DOPL also has an Advisory Pharmacy Compounding Education Committee (R156-17b-203). An out-of-state (Class D) compounding pharmacy must follow USP <795> and <797> and submit recent inspection reports (R156-17b-616; § 58-17b-308(4)).

Facility, Equipment & Purified Water Standards

USP <795> mandates that non-sterile compounding occur in a designated, controlled environment designed to prevent mix-ups, cross-contamination, and microbial adulteration:

Dedicated Compounding Space : The compounding area must be separate and distinct from routine dispensing, order processing, and patient counseling areas. It must be situated away from high-traffic flow, external doors, air vents, and direct sunlight.

Surfaces and Cleaning : Work surfaces, walls, counters, and floors must be smooth, non-porous, crack-free, and impervious to water, sanitizing agents, and active pharmaceutical ingredients. Equipment and utensils must be thoroughly cleaned and sanitized immediately before and after each compounding session.

Equipment Suitability : Measuring and weighing devices must possess certified accuracy. Balances and other measuring equipment must be suitable for the quantities weighed and must be calibrated and checked according to the manufacturer's instructions and the facility's SOPs. Utensils such as spatulas, stirring rods, mortars, and pestles must be constructed of non-reactive, non-adsorbing materials (such as stainless steel, porcelain, or borosilicate glass).

Water Quality Requirements : Water is the most common raw material and solvent used in pharmacy compounding, requiring rigorous quality distinction:

Potable (Drinking) Water : Supplied by a municipal or verified drinking water system; legally permitted only for hand washing and the initial washing and rinsing of compounding utensils.

USP Purified Water : Water purified by deionization, distillation, or reverse osmosis; strictly mandatory for the formulation of non-sterile aqueous preparations and for the final rinsing of all compounding equipment and utensils.

Note

Tap or potable water is not a compounding ingredient under USP <795>. When a formulation calls for water, use Purified Water (or a higher grade such as Sterile Water for Irrigation).

Master Formulation Record (MFR) vs. Compounding Record (CR)

A critical documentation mandate tested on the Utah MPJE is the strict administrative dichotomy between the Master Formulation Record (MFR) and the Compounding Record (CR) under USP <795>:

Master Formulation Record (MFR) — The Blueprint / Recipe

The MFR is the standard reference formulation created before compounding a preparation for the first time or when preparing batches. It represents the validated master recipe that ensures consistent potency, quality, and reproducibility across different compounding personnel. An MFR must contain:

Official or assigned name, strength, and dosage form of the preparation.

Calculations used to determine ingredient quantities.

Exact chemical names, grades, and quantities of all active pharmaceutical ingredients (APIs) and excipients.

Complete list of necessary equipment, balances, and utensils.

Step-by-step mixing and compounding instructions (including order of addition, mixing durations, temperatures).

Prescribed container-closure system (e.g., amber glass bottle with child-resistant closure).

Detailed storage requirements (e.g., "refrigerate at 2°C to 8°C; protect from light").

Quality control (QC) criteria and expected physical description (e.g., "uniform, opaque white suspension").

Assigned beyond-use date (BUD) and the scientific rationale or literature citation supporting the assigned BUD.

Compounding Record (CR) — The Specific Execution Log

The Compounding Record is the historical execution log created during each specific compounding event. It documents the individual batch or single-prescription execution of an existing MFR. A CR must include:

Official or assigned name, strength, and dosage form (referencing the specific MFR ID).

Master Formulation Record reference identifier.

Names, manufacturers, lot numbers, and expiration dates of each specific raw ingredient and chemical lot used.

Actual measured weights and volumes of each component (including initialed dual-checks).

Total quantity or yield compounded.

Assigned internal batch lot number and unique prescription number.

Assigned beyond-use date (BUD) and date/time of preparation.

Physical description and quality control testing results of the finished preparation.

Identity and signature/initials of the pharmacy technician or intern who compounded the preparation.

Identity and signature/initials of the licensed pharmacist who conducted the final verification.

Loading diagram...

Beyond-Use Dating (BUD) Limits Under Revised USP <795>

The Beyond-Use Date (BUD) represents the date or hour after which a compounded preparation may not be used, stored, or transported. Under revised USP <795>, default beyond-use dating limits have been established based on the dosage form's physical state, presence of water, and presence of antimicrobial preservatives, in the absence of formulation-specific stability-indicating study data:

Dosage Form & Formulation Type Storage Temperature Maximum Default BUD

Non-Preserved Aqueous Dosage Forms ; (e.g., oral suspensions, oral solutions, emulsions without antimicrobial preservatives) Refrigerated ; (2°C to 8°C / 36°F to 46°F) 14 Days ; (Must be refrigerated; room temp storage not permitted)

Preserved Aqueous Dosage Forms ; (e.g., topical suspensions, creams, lotions, gels, mucosal solutions containing antimicrobial preservatives) Controlled Room Temperature or Refrigerated ; (20°C to 25°C or 2°C to 8°C) 35 Days

Non-Aqueous Dosage Forms ; (e.g., suppositories, ointments, oil-based solutions, fixed oil suspensions) Controlled Room Temperature or Refrigerated ; (20°C to 25°C or 2°C to 8°C) 90 Days

Solid Dosage Forms ; (e.g., capsules, tablets, powders, troches, molded lozenges) Controlled Room Temperature or Refrigerated ; (20°C to 25°C or 2°C to 8°C) 180 Days

The Shortest Component Expiration Constraint

A core USP <795> rule is that the assigned beyond-use date may not exceed the earliest expiration date of any starting component used in the compound :

Assigned BUD = the earlier of (1) the USP <795> default limit or (2) the earliest component expiration date.

If a pharmacist compounds pediatric spironolactone oral capsules (a solid dosage form eligible for a 180-day default BUD), but the bulk spironolactone raw powder has a manufacturer expiration date occurring in 42 days, the maximum legal BUD that may be assigned is 42 days .

Extending Beyond-Use Dates

A pharmacy may assign a BUD exceeding the default USP <795> limits only when supported by a published USP-NF compounded preparation monograph or by valid, stability-indicating analytical testing performed specifically on that identical formulation, container-closure system, and storage condition.

Common MPJE Traps & Scenario Analysis

The Commercial Copy Prohibition : A physician writes a prescription for omeprazole 20 mg compounded capsules because the patient's insurance denies the commercial 20 mg capsule. Exam Trap : Under Section 503A, pharmacies cannot compound essentially copies of commercially available drugs to save patients money or circumvent third-party payer formularies. Compounding is only permitted if there is an identifiable medical difference (e.g., severe allergy to an inactive dye or excipient, or unavailability due to an official FDA shortage listing).

Reconstitution vs. Compounding : Reconstituting a commercial antibiotic powder (such as amoxicillin 250 mg/5 mL suspension) strictly in accordance with the manufacturer's package insert is dispensing/reconstitution , not compounding under USP <795>. However, adding unapproved flavoring agents, altering the diluent, or combining two commercial liquids constitutes compounding and triggers USP <795> compliance.

Office-Use Supply Requests : A local podiatrist requests 50 tubes of compounded urea 40% ointment to keep in the clinic for in-office debridement procedures. Exam Trap : Utah's office-use statute (§ 58-17b-624) allows labeled "for office use only" sales of non-controlled compounded drugs for administration in the office, but only in compliance with federal law. Under section 503A, a traditional pharmacy's compounding must be based on patient-specific prescriptions (or limited anticipatory compounding), so bulk office stock generally calls for a 503B outsourcing facility.

Aqueous Oral Suspension Storage : A technician labels a non-preserved aqueous oral suspension of baclofen with a 14-day BUD and "Store at Room Temperature." Exam Trap : Under USP <795>, non-preserved aqueous oral dosage forms must be stored in the refrigerator (2°C to 8°C) to qualify for the 14-day BUD limit.

Loading diagram... USP <795> Beyond-Use Date (BUD) Decision Tree